Psoriasis - Current and Future Players – New Research Available

London (PRWEB) October 23, 2013 -- Psoriasis - Current and Future Players

Summary

GlobalData has released its pharma report, “Psoriasis - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Psoriasis Market. The report identifies and analyses the key companies shaping and driving the global Psoriasis market. The report provides insight into the competitive Psoriasis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

-Investigation of current and future market competition for Psoriasis
-Competitor assessment
-Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
-Strategic assessment of Psoriasis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

-Gain a high level view of the trends shaping and driving Psoriasis Market
-Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
-Create an effective counter-strategy to gain a competitive advantage against those currently in the market
-What’s the next big thing in the global Psoriasis market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Drivers and Barriers – Global Issues 16
4 Current and Future Players 20
4.1 Overview 20
4.2 Trends in Corporate Strategy 24
4.3 Company Profiles 26
4.3.1 Amgen 26
4.3.2 AbbVie (Abbott) 29
4.3.3 Johnson & Johnson 31
4.3.4 Novartis 33
4.3.5 Pfizer 35
4.3.6 Eli Lilly 37
4.3.7 Merck 39
4.3.8 LEO Pharma 41
4.3.9 Celgene 44
5 Appendix 46
5.1 Bibliography 46
5.2 Abbreviations 47
5.3 Methodology 48
5.4 Forecasting Methodology 48
5.4.1 Diagnosed Psoriasis Patients 48
5.4.2 Percent Drug-Treated Patients 49
5.4.3 Drugs Included in Each Therapeutic Class 49
5.4.4 Launch and Patent Expiry Dates 50
5.4.5 General Pricing Assumptions 51
5.4.6 Individual Drug Assumptions 52
5.4.7 Generic Erosion 56
5.4.8 Pricing of Pipeline agents 56
5.5 Physicians and Specialists Included in this Study 57
5.6 Primary Research – Prescriber Survey 58
5.7 About the Authors 59
5.7.1 Analysts 59
5.7.2 Global Head of Healthcare 60
5.8 About GlobalData 61
5.9 Disclaimer 61

List of Tables

Table 1: Global Sales Forecasts ($) for Psoriasis, 2012–2022 14
Table 2: Global Psoriasis Market – Drivers and Barriers, 2012–2022 16
Table 3: Key Companies in the Psoriasis Market, 2013 22
Table 4: Amgen’s Psoriasis Portfolio Assessment, 2013 27
Table 5: Amgen’s Psoriasis SWOT Analysis, 2013 28
Table 6: Abbott’s Psoriasis Portfolio Assessment, 2013 30
Table 7: Abbott’s Psoriasis SWOT Analysis, 2013 30
Table 8: J&J’s Psoriasis Portfolio Assessment, 2013 32
Table 9: J&J’s Psoriasis Portfolio SWOT Analysis, 2013 32
Table 10: Novartis’ Psoriasis Portfolio Assessment, 2013 33
Table 11: Novartis’ Psoriasis SWOT Analysis, 2013 34
Table 12: Pfizer’s Psoriasis Portfolio Assessment, 2013 36
Table 13: Pfizer’s Psoriasis Portfolio SWOT Analysis, 2013 36
Table 14: Eli Lilly’s Psoriasis Portfolio Assessment, 2013 37
Table 15: Eli Lilly’s Psoriasis Portfolio SWOT Analysis, 2013 38
Table 16: Merck’s Psoriasis Portfolio Assessment, 2013 40
Table 17: Merck’s Psoriasis Portfolio SWOT Analysis, 2013 40
Table 18: LEO Pharma’s Psoriasis Portfolio Assessment, 2013 42
Table 19: LEO Pharma’s Psoriasis Portfolio SWOT Analysis, 2013 43
Table 20: Celgene’s Psoriasis Portfolio Assessment, 2013 44
Table 21: Celgene’s Psoriasis Portfolio SWOT Analysis, 2013 45
Table 22: Key Launch Dates 50
Table 23: Key Patent Expiries 50
Table 24: Physicians Surveyed, By Country 58

List of Figures

Figure 1: Global Sales for Psoriasis by Region, 2012–2022 15
Figure 2: Company Portfolio Gap Analysis in Psoriasis, 2012–2022 23

Companies Mentioned

Amgen
AbbVie (Abbott)
Johnson & Johnson
Novartis
Pfizer
Eli Lilly
Merck
LEO Pharma
Celgene

Read the full report:

Psoriasis - Current and Future Players

http://www.reportbuyer.com/pharma_healthcare/diseases/psoriasis_current_future_players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]